Table 1 Clinical characteristic of molecular subtype groups
Characteristic | Overall (n = 157) | Luminal A (n = 48) | Luminal B (n = 64) | HER2 (n = 27) | TNBC (n = 18) |
|---|---|---|---|---|---|
Age | 51.00(45.00,58.00) | 49.50(46.50,60.25) | 50.00(43.00,59.00) | 55.00(51.00,56.00) | 52.50(45.75,57.50) |
BMI | 23.05(21.37,25.30) | 23.10(21.42,26.39) | 23.23(21.76,24.94) | 22.19(20.11,24.56) | 23.00(22.29,24.59) |
Menopause | 79 (50%) | 21 (44%) | 30 (47%) | 18 (67%) | 10 (56%) |
Lymph node metastasis | 45 (29%) | 8 (17%) | 22 (34%) | 8 (30%) | 7 (39%) |
Her-2 | Â | Â | Â | Â | Â |
 Negative | 119 (76%) | 48 (100%) | 53 (83%) | 0 (0%) | 18 (100%) |
 Positive | 38 (24%) | 0 (0%) | 11 (17%) | 27 (100%) | 0 (0%) |
Ki-67 | Â | Â | Â | Â | Â |
 Negative | 55 (35%) | 48 (100%) | 4 (6.3%) | 1 (3.7%) | 2 (11%) |
 Positive | 102 (65%) | 0 (0%) | 60 (94%) | 26 (96%) | 16 (89%) |
ER | Â | Â | Â | Â | Â |
 Negative | 45 (29%) | 0 (0%) | 0 (0%) | 27 (100%) | 18 (100%) |
 Positive | 112 (71%) | 48 (100%) | 64 (100%) | 0 (0%) | 0 (0%) |
PR | Â | Â | Â | Â | Â |
 Negative | 64 (41%) | 4 (8.3%) | 15 (23%) | 27 (100%) | 18 (100%) |
 Positive | 93 (59%) | 44 (92%) | 49 (77%) | 0 (0%) | 0 (0%) |
Histologic grade | Â | Â | Â | Â | Â |
 I | 17 (11%) | 9 (19%) | 8 (13%) | 0 (0%) | 0 (0%) |
 II | 87 (55%) | 28 (58%) | 41 (64%) | 12 (44%) | 6 (33%) |
 III | 28 (18%) | 0 (0%) | 12 (19%) | 8 (30%) | 8 (44%) |
Differentiated degree | Â | Â | Â | Â | Â |
 Medium differentiated | 87 (55%) | 28 (58%) | 41 (64%) | 12 (44%) | 6 (33%) |
 Low differentiated | 27 (17%) | 0 (0%) | 11 (17%) | 8 (30%) | 8 (44%) |
 High differentiated | 16 (10%) | 9 (19%) | 7 (11%) | 0 (0%) | 0 (0%) |